N-(3-(二甲胺基)丙基)-4-(8-羟基喹啉-6-基)苯甲酰胺 | 1222800-79-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: N-(3-(二甲胺基)丙基)-4-(8-羟基喹啉-6-基)苯甲酰胺
• 中文别名: N-(3-(二甲氨基)丙基)-4-(8-羟基喹啉-6-基)苯甲酰胺
• 英文名称: N-(3-(Dimethylamino)propyl)-4-(8-hydroxyquinolin-6-yl)benzamide
• 英文别名: N-[3-(dimethylamino)propyl]-4-(8-hydroxyquinolin-6-yl)benzamide
• CAS: 1222800-79-4
• 化学式: C₂₁H₂₃N₃O₂
• 分子量: 349.4
• InChiKey: QDBVSOZTVKXUES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  65.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

文献信息

• METHOD OF PREVENTING OR TREATING VIRAL INFECTION
  申请人：Department of Health and Human Services The United States of America, as Represented by the Secretary,

  公开号：US20130123344A1

  公开（公告）日：2013-05-16

  Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.
• METHODS OF TREATING HEPATITIS B VIRUS
  申请人：Gilead Sciences, Inc.

  公开号：US20160303095A1

  公开（公告）日：2016-10-20

  The present invention relates to novel methods of treating Hepatitis B Virus by administering a KDM5 inhibitor.
• PREVENTING OR TREATING VIRAL INFECTION BY INHIBITION OF THE HISTONE METHYLTRANSFERASE EZH1 OR EZH2
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Serv

  公开号：US20180071284A1

  公开（公告）日：2018-03-15

  Disclosed are methods of preventing or treating a viral infection of a host, the method comprising administering to the host an effective amount of an inhibitor of the histone methyltransferase activity of EZH1 or EZH2. In one embodiment, the method comprises administering to the host an effective amount of a compound of Formula (I): wherein X 1 , X 2 , R 1 , R 2 , and R 3 are defined herein; or pharmaceutically acceptable salts, solvates, or stereoisomers thereof. In another embodiment, the present invention provides a method of inhibiting an EZH1 or EZH2 methyltransferase in a virus-infected host, the method comprising administering to the host an effective amount of a compound of Formula (I) as defined above. In another embodiment, the present invention provides a method of improving the therapeutic effect of a pharmaceutical composition, the method comprising adding to the pharmaceutical composition a compound of Formula (I) as defined above.
• COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION
  申请人：Children's National Medical Center

  公开号：US20210198669A1

  公开（公告）日：2021-07-01

  The present disclosure relates to compositions comprising an antisense RNA sequence comprising a region of complementarity that is substantially complementary to an miRNA. Pharmaceutical compositions comprising the antisense RNA molecule, optionally further comprising an anti-inflammatory corticosteroid are also disclosed. Methods of treating or preventing inflammation, a steroid side effect, or a muscle disease using the one or the pharmaceutical compositions are also disclosed.
• METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES
  申请人：University of Houston System

  公开号：US20220202792A1

  公开（公告）日：2022-06-30

  The present disclosure provides methods and formulations for treating a patient suffering from one or more of chronic inflammatory injury, metaplasia, dysplasia or cancer of an epithelial tissue, which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or differentiation of pathogenic epithelial stem cells (PESCs) relative to normal epithelial stem cells in the tissue in which the PESCs are found. Representative epithelial tissues include pulmonary, genitourinary, gastrointestinal/esophageal, pancreatic and hepatic tissues.